Branford, S <br/><br/>
Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.  [electronic resource] 

 -  Leukemia  Dec 2003 
 - 2401-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>0887-6924 
<br/><br/><label>Standard No.: </label>10.1038/sj.leu.2403158  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antimetabolites, Antineoplastic--administration & dosage<br/>Antineoplastic Agents--administration & dosage<br/>Benzamides<br/>Bone Marrow--metabolism<br/>Cross-Over Studies<br/>Cytarabine--administration & dosage<br/>Cytogenetics<br/>DNA Mutational Analysis<br/>Fusion Proteins, bcr-abl--blood<br/>Humans<br/>Imatinib Mesylate<br/>Interferon-alpha--administration & dosage<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--diagnosis<br/>Phosphotransferases--chemistry<br/>Piperazines--administration & dosage<br/>Prognosis<br/>Protein Structure, Tertiary<br/>Pyrimidines--administration & dosage<br/>Treatment Outcome